Why are Zoetis' 2012 executive bonuses being determined by Pfizer?

In 2012, Zoetis was a part of Pfizer. Therefore, the Named Executive Officers (NEOs) of Zoetis were employees of Pfizer and participated in Pfizer's annual incentive plan, the Global Performance Plan (GPP). The awards were approved by Pfizer's Compensation Committee.

How were the 2012 annual incentive awards for Zoetis' NEOs calculated?

The awards were determined by a combination of factors: Pfizer's overall financial performance (weighted 40% revenue, 40% adjusted diluted EPS, 20% cash flow), the financial performance of the animal health business unit, the achievement of specific strategic and operational goals for each executive's role, and an assessment of individual performance by Pfizer's CEO.

Did Pfizer and the Zoetis business unit perform well enough to fund the incentive pools?

Yes, Pfizer's 2012 performance exceeded targets for revenue and adjusted diluted EPS, and met the threshold for cash flow, resulting in a 120% GPP funding pool of target. The animal health business unit's performance also contributed positively, resulting in a 115% funding pool of target for that segment.

What were the total incentive payouts for the top executives?

The non-equity incentive plan compensation for fiscal year 2012 ranged from $174,900 for Dr. Knupp and Mr. Lewis to $500,000 for CEO Juan Ramón Alaix. Total compensation figures, including other elements, are also provided, with Mr. Alaix receiving the highest total at $2,587,567.

ZTS 8-K: Leadership Changes

Summary

This 8-K filing from Zoetis Inc. (ZTS), filed on March 5, 2013, primarily details the determination of annual incentive awards for the company's Named Executive Officers (NEOs) for fiscal year 2012. Since Zoetis was part of Pfizer during 2012, these awards were determined under Pfizer's Global Performance Plan (GPP). The filing provides insight into how both Pfizer's overall performance and Zoetis' specific business unit performance influenced these executive bonuses. Key takeaways for investors include the strong performance metrics achieved by Pfizer in 2012, which exceeded targets for revenue and adjusted diluted earnings per share and met the threshold for cash flow. This robust performance directly contributed to the funding of the incentive pools. The filing also outlines the individual performance objectives and strategic goals that the NEOs were evaluated against, reinforcing that these executives were recognized for exceeding their overall objectives for the year, as reflected in their incentive payouts and total compensation figures.

Key Highlights

1Determination and payment of 2012 annual incentive awards for Zoetis' Named Executive Officers (NEOs).
2Awards were determined under Pfizer's Global Performance Plan (GPP), which is based on Pfizer's overall financial performance (revenue, adjusted diluted EPS, cash flow).
3Pfizer's 2012 financial performance exceeded targets for revenue ($59.2B actual vs. $59.0B target) and adjusted diluted EPS ($2.26 actual vs. $2.17 target), and met the threshold for cash flow ($18.4B actual vs. $15.5B threshold).
4Zoetis' animal health business unit also showed strong performance, contributing to incentive pool funding.
5NEOs' awards were also based on business unit/function financial performance, strategic/operational goals, and individual performance assessments.
6All NEOs were determined to have exceeded their overall objectives for 2012.
7The filing details the specific incentive award amounts and total compensation for each NEO for fiscal year 2012.

Zoetis Inc. 8-K Report, Executive Changes (Mar 5, 2013)

Summary

Key Highlights

Frequently Asked Questions